For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 9,121 | 20,014 | ||
| General and administrative | 20,396 | 12,103 | ||
| Total operating expenses | 29,517 | 32,117 | ||
| Loss from operations | -29,517 | -32,117 | ||
| Interest income | 1,012 | 1,261 | ||
| Interest expense | 71 | 71 | ||
| Change in fair value of warrant liability | -2,021 | 5,802 | ||
| Total other income (expenses) | 2,962 | -4,612 | ||
| Net loss | -26,555 | -36,729 | ||
| Dividends on series b-1 preferred stock | - | 1,095 | ||
| Unrealized loss on marketable securities, net | 1 | - | ||
| Net loss attributable to common stockholders | - | -37,824 | ||
| Net comprehensive loss | -26,556 | - | ||
| Basic EPS | -1.67 | -0.56 | ||
| Diluted EPS | -1.67 | -0.56 | ||
| Basic Average Shares | 15,886,876 | 66,985,129 | ||
| Diluted Average Shares | 15,886,876 | 66,985,129 | ||
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)